EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CircSPECC1 attenuates sensitivity to PD-1 blockade through impaired antigen presentation in hepatocellular carcinoma

Rui Peng, Jiahao Zhang, Chi Zhang, Bingbing Su, Songsong Fan, Yongzhi Chen, Qian Wang, Guoqing Jiang, Li Ding, Xin Jin, Liping Wang, Jun Cao und 2 weitere

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Rui Peng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital affiliated to Yangzhou University, No. 98 West Nantong Road, Yangzhou, Jiangs…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Graduate Research and Innovation Projects of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) demonstrate therapeutic benefits in advanced hepatocellular carcinoma (HCC), yet most patients exhibit limited responses to anti-PD-1 therapy and the molecular basis underlying this resistance remains largely undefined. Here, we identified the circular RNA SPECC1 (circSPECC1) as a regulator of antigen presentation and a crucial factor influencing the efficacy of anti-PD-1 therapy. circSPECC1 was significantly elevated in tumor tissues of HCC patients showing resistance to anti-PD-1 therapy and correlated with diminished intratumoral CD8+ T-cell infiltration. Elevated circSPECC1 levels facilitated tumor progression and impaired the therapeutic efficacy of anti-PD-1 treatment. Overexpression of circSPECC1 in cancer cells suppressed the proliferation and cytotoxic activity of CD8+ T cells both in vitro and in vivo. Mechanistically, circSPECC1 bound to the peptide-loading complex (PLC) chaperone ERP57 and disrupted its interaction with TAPBP (TAP binding Protein), thereby destabilizing PLC integrity. This aberrant interaction redirected MHC-I toward ER-associated degradation (ERAD), suppressing surface antigen presentation and impairing CD8+ T-cell activation. Importantly, targeted silencing of circSPECC1 using a PEG-PEI-folate nanosystem encapsulating si-circSPECC1 significantly restored sensitivity both murine and patient-derived xenograft HCC models to PD-1 blockade. In summary, these findings uncover a novel circRNA-guided ERAD of MHC-I mechanism that impairs antitumor immunity and highlight circSPECC1 as a promising therapeutic target to overcome immunotherapy resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAntigen PresentationRNA, CircularHumansAnimalsMiceCD8-Positive T-LymphocytesDrug Resistance, NeoplasmCell Line, TumorFemaleXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Anti-PD-1 resistanceCircular RNACombination therapyEndoplasmic-reticulum-associated degradationMajor histocompatibility complex-1

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsRNA, CircularPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital affiliated to Yangzhou University, No. 98 West Nantong Road, Yangzhou, Jiangsu, 225009, China.
  • Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital affiliated to Yangzhou University, No. 98 West Nantong Road, Yangzhou, Jiangsu, 225009, China; General Surgery Institute of Northern Jiangsu People…
  • Department of General Surgery, Taizhou People's Hospital affiliated to Nanjing Medical University, Jiangsu, 225300, China.
  • Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital affiliated to Yangzhou University, No. 98 West Nantong Road, Yangzhou, Jiangsu, 225009, China; Department of Hepatobiliary Surgery, Hunan Provincia…
  • Department of Biobank, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China.

Förderung

  • National Natural Science Foundation of China
  • Graduate Research and Innovation Projects of Jiangsu Province

Zitieren

APA

Peng, R., Zhang, J., Zhang, C., Su, B., Fan, S., Chen, Y., Wang, Q., Jiang, G., Ding, L., Jin, X., Wang, L., Cao, J., Jin, S., & Bai, D. (2026). CircSPECC1 attenuates sensitivity to PD-1 blockade through impaired antigen presentation in hepatocellular carcinoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218568

Vancouver

Peng R, Zhang J, Zhang C, Su B, Fan S, Chen Y, et al. CircSPECC1 attenuates sensitivity to PD-1 blockade through impaired antigen presentation in hepatocellular carcinoma. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218568

BibTeX
@article{Peng2026,
  author = {Peng, Rui and Zhang, Jiahao and Zhang, Chi and Su, Bingbing and Fan, Songsong and Chen, Yongzhi and Wang, Qian and Jiang, Guoqing and Ding, Li and Jin, Xin and Wang, Liping and Cao, Jun and Jin, Shengjie and Bai, Dousheng},
  title = {CircSPECC1 attenuates sensitivity to PD-1 blockade through impaired antigen presentation in hepatocellular carcinoma},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218568}
}
Kostenlos starten →